Glentra Capital P/S
Alternative investment fund manager authorised by the Finanstilsynet since 22/12/2022; manages 3 registered funds.
www.glentra.com/team ↗Details
- Type
- Venture Capital
- Headquarters
- 2., Denmark
- AUM
- 323,002,636.00
Similar investors in Denmark
Lovemondays
https://lovemondays.dk/wp-content/uploads/2023/02/IMG_9094-3.mov https://lovemondays.dk/wp-content/uploads/2023/02/IMG_9094-3.mov WE INSPIRE GREAT TEAMS TO SCALE BIG A Venture capital fund backed by lehrmann family We inspire great teams to scale big A VENTURE CAPITAL FUND BACKED BY LEHRMANN FAMILY Looking for Nordic seed stage SaaS, Marketplaces and Consumer businesses. Initial ticket size 1-3m EUR potential big follow up. Become one of the few
Bumble Ventures
In a post-AI world of infinite supply, human attention is the ultimate scarce resource . We invest in the proprietary audiences, communities, and IP that hold, compound, and monetize that scarcity. As hyper commoditization strips software and content of pricing power, controlling the last mile - the direct, un-intermediated relationship with the consumer - has become the single most critical choke point for enterprise value.
zefyr invest a/s
Vores formål Zefyr Invest A/S' investeringer omfatter virksomheder, der som led i en fortsat ekspansion og udvikling har behov for tilførsel af ledelsesmæssige ressourcer og/eller finansiering via egenkapital. Disse investeringer består af veletablerede nichevirksomheder, som drives af et selvstændigt ledelsesteam på investeringstidspunktet. Læs mere Vores værdier Vi værdsætter traditionelle værdier med stor vægt på høj
vxc holding aps
Vi kigger udelukkende efter ild i øjnene på de folk vi arbejder med VXC er en forretnings-/konceptudviklingsvirksomhed med speciale i teknologiske projekter. Vi har hovedsæde i København og har eksisteret på det danske marked siden 2010. VXC er i dag et privatejet selskab, med partnere i stærke ledelsesteams investerer i udvikling af virksomheder
Seed Capital
We back exceptional Nordic-based founders all the way to exit. More than 70% of our companies convert from seed to Series A, making us one of the best-performing funds in Europe. We’ve made 60 investments, 10 exits and 5 IPOs over the past two decades and have just raised €140M for our next fund.
nb capital aps
Representative Investments by Florian Schönharting Role: Co-Founder Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and autoimmune diseases, based on proprietary next generation antibody technologies. Ticker: GEN.CO - Market cap: